Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

(2014) Matthew M. K. Chan et al.   CANCER

Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target

(2014) G. Chen et al.   CLINICAL CANCER RESEARCH

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid

(2014) Edwin Lok et al.   MELANOMA RESEARCH

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

(2014) Matteo S. Carlino et al.   Molecular Oncology

Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells

(2014) C S Manning et al.   ONCOGENE

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

(2014) Alexander M. Menzies et al.   PLoS One

Emerging insights into resistance to BRAF inhibitors in melanoma

(2013) Amanda D. Bucheit et al.   BIOCHEMICAL PHARMACOLOGY

Patterns of response and progression in patients withBRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

(2013) Mary W. F . Azer et al.   CANCER

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS

(2013) Dionysis Papadatos-Pastos et al.   Expert Review of Anticancer Therapy

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion

(2012) Eishu Hirata et al.   JOURNAL OF CELL SCIENCE

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine

(2012) J. S. Wilmott et al.   MOLECULAR CANCER THERAPEUTICS

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

(2012) Heike Niessner et al.   Cancer Medicine

Strategies to optimize the brain availability of central nervous system drug candidates

(2011) Travis T Wager et al.   Expert Opinion on Drug Discovery

Development of an optimized backbone of FRET biosensors for kinases and GTPases

(2011) Naoki Komatsu et al.   MOLECULAR BIOLOGY OF THE CELL

Cerebrospinal Fluid IL-6, TNF-α and MCP-1 in Children with Acute Lymphoblastic Leukaemia during Chemotherapy

(2011) P. Protas et al.   NEUROPEDIATRICS

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

(2009) Nathalie Dhomen et al.   CANCER CELL

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

(2008) Li Liu et al.   Jove-Journal of Visualized Experiments